/
NUVB
$5.61-$0.04 (-0.71%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$2.0B
348M shares
52-week range
$1.87 – $9.75
47% from low
Sector
PHARMACEUTICAL PREPARATIONS
Exchange
NYSE
CS
Borrow rate
0.28%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-3.70
Nuvation Bio Inc.
Nuvation Bio Inc is a biopharmaceutical company tackling unmet needs in oncology by developing differentiated and novel therapeutic candidates. Its product candidate, taletrectinib, is an oral, potent, central nervous system-active, selective, next-generation c-ros oncogene 1 (ROS1) inhibitor designed for the treatment of patients with ROS1+ non-small cell lung cancer (NSCLC). In addition, its clinical-stage pipeline includes oncology product candidates such as Safusidenib, NUV-1511, and NUV-868 in different stages of development. The Company generates revenue from out-licensing collaborative agreements, including product revenue, upfront license fees, royalty revenue, and research and development services revenue. The Company generates the majority of its revenue from Japan.
www.nuvationbio.com- Employees
- 307
- IPO / List date
- Feb 10, 2021
- HQ
- NEW YORK, NY
Held by traders on TradeandTell
No one on the platform currently holds NUVB.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 559,180 | $2.4M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded NUVB yet.
